Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomarin Pharmaceuticals (NQ: BMRN )

69.93 +0.91 (+1.32%)
Streaming Delayed Price Updated: 10:05 AM EDT, Sep 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 101,123
Open 69.21
Bid (Size) 69.88 (1)
Ask (Size) 69.97 (2)
Prev. Close 69.02
Today's Range 68.70 - 70.13
52wk Range 67.75 - 99.56
Shares Outstanding 183,352,255
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Investors should take note of NASDAQ:BMRN, a growth stock that remains attractively priced.
Despite its growth, BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN) remains within the realm of affordability. 
Via Chartmill
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish
BioMarin Pharmaceutical aims to achieve $4 billion in revenue by 2027, driven by Voxzogo adoption, despite emerging competition from Ascendis Pharma. Goldman Sachs maintains a "Buy" rating with a $139... 
Via Benzinga

Performance

YTD
-28.68%
-28.68%
1 Month
-22.28%
-22.28%
3 Month
-17.97%
-17.97%
6 Month
-21.08%
-21.08%
1 Year
-20.59%
-20.59%

More News

Read More
Investors should take notice of NASDAQ:BMRN—it offers a great deal for the fundamentals it presents.
Via Chartmill
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $14,000 Today
Via Benzinga
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Via Benzinga
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
Via Benzinga
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
Via Benzinga
Beyond The Numbers: 11 Analysts Discuss Biomarin Pharmaceutical Stock
Via Benzinga
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
Via Benzinga
Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug
Via Investor's Business Daily
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
Via Benzinga
Exposures Product Safety
BioMarin Restructures, Outlines Roadmap To $4B Revenues By 2027
Via Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN.
Via Chartmill
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (14 Ratings)
Via Benzinga
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
Via Benzinga
NASDAQ:BMRN is showing good growth, while it is not too expensive.
Via Chartmill
Wall Street's Top 10 Stock Calls This Week - Saturday, Aug. 24
Via Talk Markets
Palo Alto Networks To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
NASDAQ:BMRN is not too expensive for the growth it is showing.
Via Chartmill
$1000 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance
Via Benzinga
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Biomarin Pharmaceutical Analysts Boost Their Forecasts Following Better-Than-Expected Q2 Results
Via Benzinga
BMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.